Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen: We Expect To Double Biosimilar Sales By 2030

Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue

Executive Summary

Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.

You may also be interested in...

Amgen Forecasts ‘High Teens’ Growth For Biosimilars

Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.

US Amjevita Sales Slide By Almost Two-Thirds

Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.

Is The Bloom Off The Rose For Big Pharma And Biosimilars?

After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts